Nano-liposomal encapsulation of isorhamnetin to enhance bioavailability and anticancer efficacy
TL;DR
NLPs improved Iso's bioavailability and anticancer efficacy, supporting their potential for further studies in breast cancer therapy and supporting their potential for further studies in breast cancer therapy.
Abstract
Abstract This study aimed to improve the bioavailability and anticancer efficacy of isorhamnetin (Iso), a flavonoid with poor water solubility, by encapsulating it into nanoliposomes and evaluating their effects. Iso-loaded nanoliposomes (Iso.NLP) were prepared via thin-film hydration and characterised for particle size, morphology, polydispersity index (PDI), zeta potential, and entrapment efficiency (EE%). In vitro drug release, stability at 4 °C, cytotoxicity against MCF-7 cells, and cellular uptake using FITC-labelled Iso.NLP were assessed. Optimised Iso.NLP were spherical (101–168 nm) with zeta potentials of −16.5 to −4.5 mV and EE% of 87–94%. Iso.NLP2 showed sustained release (∼65% in 24 h vs. 100% free Iso in 6 h), stable for ≥10 days at 4 °C. MTT assay revealed higher cytotoxicity for Iso.NLP2 (42.5% viability) versus free Iso (71.2%, 4 µM; p < 0.01). Cellular uptake was markedly enhanced. Iso.NLPs improved Iso’s bioavailability and anticancer efficacy, supporting their potential for further studies in breast cancer therapy.